These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29781078)

  • 1. Prediction of preeclampsia developing at term.
    Huluta I; Panaitescu AM
    Ginekol Pol; 2018; 89(4):217-20. PubMed ID: 29781078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
    Tsiakkas A; Saiid Y; Wright A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2016 Jul; 215(1):87.e1-87.e17. PubMed ID: 26875953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
    Wright D; Krajewska K; Bogdanova A; Wright A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jun; 47(6):755-61. PubMed ID: 26726123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASPRE trial: performance of screening for preterm pre-eclampsia.
    Rolnik DL; Wright D; Poon LCY; Syngelaki A; O'Gorman N; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Papaioannou G; Tenenbaum-Gavish K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Oct; 50(4):492-495. PubMed ID: 28741785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain).
    Perales A; Delgado JL; de la Calle M; García-Hernández JA; Escudero AI; Campillos JM; Sarabia MD; Laíz B; Duque M; Navarro M; Calmarza P; Hund M; Álvarez FV;
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):373-382. PubMed ID: 27883242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
    Dragan I; Georgiou T; Prodan N; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Jan; 49(1):73-77. PubMed ID: 27619203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy.
    Crovetto F; Figueras F; Triunfo S; Crispi F; Rodriguez-Sureda V; Peguero A; Dominguez C; Gratacos E
    Fetal Diagn Ther; 2014; 35(4):258-66. PubMed ID: 24714555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of preeclampsia in primigravida in late first trimester using serum placental growth factor alone and by combination model.
    Agarwal R; Chaudhary S; Kar R; Radhakrishnan G; Tandon A
    J Obstet Gynaecol; 2017 Oct; 37(7):877-882. PubMed ID: 28569565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
    Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
    Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia.
    Akolekar R; Zaragoza E; Poon LC; Pepes S; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Nov; 32(6):732-9. PubMed ID: 18956425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.
    Andersen LB; Dechend R; Jørgensen JS; Luef BM; Nielsen J; Barington T; Christesen HT
    Hypertens Pregnancy; 2016 Aug; 35(3):405-19. PubMed ID: 27159383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia.
    Frusca T; Gervasi MT; Paolini D; Dionisi M; Ferre F; Cetin I
    J Matern Fetal Neonatal Med; 2017 Sep; 30(18):2166-2173. PubMed ID: 27737599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
    Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):194-202. PubMed ID: 26094952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor®.
    Dröge LA; Höller A; Ehrlich L; Verlohren S; Henrich W; Perschel FH
    Pregnancy Hypertens; 2017 Apr; 8():31-36. PubMed ID: 28501276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
    Lai J; Garcia-Tizon Larroca S; Peeva G; Poon LC; Wright D; Nicolaides KH
    Fetal Diagn Ther; 2014; 35(4):240-8. PubMed ID: 24853452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.